CHEMED CORP
No enriched coverage for $CHE in the last 7 days.
Chemed Corporation (NYSE: CHE) will release its Q3 2026 earnings on October 27, 2026, and host a conference call on October 28, 2026, to discuss results and business updates. The company operates VITAS Healthcare and Roto-Rooter, and warns that forward-looking statements involve risks and uncertainties.
MCNAMARA KEVIN J (president and CEO) sold 2,000 shares of CHEMED CORP (CHE) at $513.45 ($1.03M total) on 2026-09-28.
Analysts made multiple rating changes: Wells Fargo initiated Johnson Controls (JCI) as overweight, UBS initiated Chemed (CHE) as buy, Mizuho reiterated SpaceX as outperform, Barclays initiated Ligand Pharmaceuticals (LGND) as overweight, Seaport reiterated Nvidia (NVDA) as sell, UBS upgraded Stem (STEM) to buy, HSBC upgraded BP (BP) to buy, Bernstein initiated CF Industries (CF) as outperform, Bank of America reiterated AMD (AMD) as buy, Bernstein reiterated Apple (AAPL) as outperform, JPMorgan…
Recent CHE coverage spans insider activity, earnings and financial news.
In the last 30 days, CHE insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.0M). The most active reporter was MCNAMARA KEVIN J, president and CEO, with 1 filing.
The announcement sets the date for the earnings release, with no new financial data disclosed.
The insider sale may signal reduced confidence from the CEO and could weigh on the stock.
Buy initiation may boost demand.
Analyst upgrade and strong earnings suggest upside potential.
The deal adds a $50‑55 M revenue stream and creates potential margin upside, but valuation multiples and integration risk introduce uncertainty.
AlphAI scores every news story that mentions CHE with an AI model for sentiment and relevance, and aggregates insider trades from CHEMED CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Chemed Corporation (NYSE: CHE) will release its Q3 2026 earnings on October 27, 2026, and host a conference call on October 28, 2026, to discuss results and business updates. The company operates VITAS Healthcare and Roto-Rooter, and warns that forward-looking statements involve risks and uncertainties.
1 min readMCNAMARA KEVIN J (president and CEO) sold 2,000 shares of CHEMED CORP (CHE) at $513.45 ($1.03M total) on 2026-09-28.
1 min readAnalysts made multiple rating changes: Wells Fargo initiated Johnson Controls (JCI) as overweight, UBS initiated Chemed (CHE) as buy, Mizuho reiterated SpaceX as outperform, Barclays initiated Ligand Pharmaceuticals (LGND) as overweight, Seaport reiterated Nvidia (NVDA) as sell, UBS upgraded Stem (STEM) to buy, HSBC upgraded BP (BP) to buy, Bernstein initiated CF Industries (CF) as outperform, Bank of America reiterated AMD (AMD) as buy, Bernstein reiterated Apple (AAPL) as outperform, JPMorgan…
3 min readUBS initiated coverage on Chemed Corp. (NYSE: CHE) with a buy rating and a $650 price target, citing low double-digit EPS growth outlook. The stock trades at $495.65, below UBS's fair value estimate of $570.59. Chemed reported strong Q2 earnings, exceeding expectations, driven by growth in its VITAS hospice unit and steady Roto-Rooter results. The company raised its outlook, highlighting improved operating leverage.
1 min readChemed Corporation (NYSE:CHE) acquired a Roto-Rooter franchise for $60.6M, serving 11M people with $50M-$55M annual revenue. The purchase price is 1.10-1.21x historical revenue. Chemed aims to improve profitability through direct control, but risks include higher operating costs and integration challenges. Hedge fund holdings decreased slightly before the acquisition.
2 min readMCNAMARA KEVIN J (president and CEO) sold 2,000 shares of CHEMED CORP (CHE) at $501.40 ($1.00M total) on 2026-09-18.
1 min readLEE SPENCER S (executive vice president) sold 1,000 shares of CHEMED CORP (CHE) at $541.04 ($0.54M total) on 2026-08-21.
1 min readMCNAMARA KEVIN J (president and CEO) sold 2,000 shares of CHEMED CORP (CHE) at $541.16 ($1.08M total) on 2026-08-21.
1 min readChemed (CHE) raised its quarterly dividend to $0.70 per share, payable Sept. 3, 2026, up $0.10 from the prior payment, marking 221 consecutive quarterly payouts. The company reported Q2 2026 net income of $67.7 million and higher EPS year over year. The article links the dividend and earnings beat to Chemed’s capital allocation and 2029 revenue and earnings projections.
6 min readBiotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.
7 min read
